Akeso and Dawnrays Biotechnology’s Ebronucimab (PCSK9 mAb) Reports Early Completion of Patient Enrollment in P-III Trial for Primary Hypercholesterolemia and Mixed Hyperlipidemia
Shots:
- Ebronucimab demonstrated a similar safety profile vs. the marketed PCSK9 mAb drugs with the same target, with drug-related AEs >5% and higher than PBO which only included the injection-site adverse reactions
- The results showed that Ebronucimab (450 mg, Q4W) can reduce LDL-C by 65.48% from baseline & 65.69% from the PBO arm; and 150 mg, Q2W can reduce LDL-C by 63.69% from baseline & 63.90% from the PBO arm
- Additionally, the company expects that Ebronucimab will be approved for marketing soon, which will provide a better choice for huge no. of cardiovascular patients in China
Ref: PR Newswire | Image: Akeso
Click here to read the full press release
Tags
Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com
